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Abstract
The incidence and the mortality of cancer increase with age. This article explores the possibility of decreasing cancer-
related mortality in the aged with secondary prevention of cancer deaths that entails early diagnosis of cancer through the 
screening of asymptomatic older individuals. 
We establish that screening of asymptomatic individuals should be based on physiologic rather than chronologic age that 
may be estimated from a comprehensive geriatric assessment and possibly with the utilization of biologic markers of aging.
It is reasonable to offer some form of screening for lung and colorectal cancer to individuals with a life expectancy of at least 
five years and screening for breast and prostate cancer to women and men respectively with a life expectancy of at least ten 
years. The ideal number of screening sessions and the ideal interval between screening sessions is unestablished.
The aging of the population, the diversity of the older population, the development of new and more sensitive screening 
interventions, the discovery of new biologic markers of cancer and age represent the main challenges in studying the value 
of cancer screening in the aged. Probably the most reliable information may be obtained from rapid-learning databases in 
which information related to each person's physiologic age is included.
Introduction
Worldwide, the incidence and prevalence of cancer 
increase with age [1]. In the meantime the risk of cancer-
related mortality increases with age at diagnosis [2-4]. As 
the world population is aging, cancer in the older person 
is an ever more common problem, and the reduction of 
cancer deaths in older individuals represents the most 
urgent goal of cancer control. In this article we explore 
secondary cancer prevention as representing a strategy to 
reduce the risk of mortality in the aged. This hypothesis 
is based on four considerations:
i. Several studies showed that the practice of screening 
asymptomatic individuals for cancer becomes less common 
with the aging of the population [5].
ii. The average life expectancy of the Western population 
is rapidly increasing1. Consequently the benefits of early 
detection of cancer that emerges several years after diagnosis 
may be present even for those undergoing screening at an 
advanced age. 
iii. New forms of cancer treatment, including minimally 
invasive surgery [6], stereotactic radio surgery [7], and 
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targeted systemic therapy [8], are associated with decreased 
risk of complications. They may be safely utilized in 
individuals with limited tolerance of stress who might be 
hurt by more aggressive treatments.
It is now possible to personalize cancer screening 
according to individual life expectancy and tolerance 
of stress, as the estimate of a person's physiologic age is 
becoming more precise [1,9].
After reviewing the principles and the effectiveness 
of cancer screening and early detection, this article 
will explore the benefits and risks of secondary cancer 
prevention in older individuals. In particular we will 
review the current evidence and the limitations of 
previous clinical trials. At the end we will propose a 
conceptual framework to guide the screening of older 
individuals for cancer, and we will propose a research 
agenda.
Principles of Cancer Screening and Early De-
tection
In this section we will examine the assumptions that jus-
tify secondary cancer prevention, the endpoints of clinical 
trials, the ideal characteristics of the screening test and the 
potential advantages and disadvantages of screening as-
ymptomatic older individuals for cancer [10].
Assumptions that justify secondary cancer pre-
vention
Three assumptions underlie the employment of can-
cer screening and early detection:
i. There is an early, asymptomatic stage when cancer 
may be diagnosed with screening.
ii. Treatment of cancer at an early, asymptomatic stage 
is associated with improved chances of cure.
iii. The risks of the treatment are minimal when com-
pared with the potential benefits.
Cost considerations may be involved in the decision 
to implement cancer screening as a public health policy. 
Budget restrictions compel governments to prioritize the 
policies that will produce the best return for the lowest 
investment. By necessity, this determination is arbitrary. 
In the USA a policy is considered cost effective when the 
cost per year of life saved is equivalent to or lower than 
the cost of one year of life with kidney dialysis [11].
End point of clinical trials and related questions
There is consensus that the only acceptable end point of 
clinical trials of secondary cancer prevention is a reduction 
of the cancer-related mortality in the screened population. 
Intermediate end points proposed in the past have proven 
flawed and should not be entertained [10] (Table 1).
When dealing with older individuals, it is legitimate to 
ask if alternative endpoints should be considered, such as 
prolongation of overall survival, prolongation of active life 
expectancy, and improvement of quality of life [12]. With 
the aging of the population, cancer becomes a major cause 
of mortality, and it is reasonable to expect that a reduction 
in cancer deaths may be associated with improved overall 
survival. In the meantime it is important to establish that 
the price of reduced mortality does not include functional 
dependence and compromised quality of life.
The ideal screening test
It is self-evident that a screening test should be min-
imally invasive and reasonably priced [10]. A new prob-
lem emerged in an era of precision technology: screen-
ing tests may lead to unnecessary interventions that may 
increase the risk and the cost of screening. The cause 
of this problem is twofold. First, some new tests are so 
sensitive that they detect an excess of cancer that may 
never become clinically relevant. For example, the diag-
nostic yield of breast MRI or three-dimensional mam-
mography is superior to that of conventional or digital 
mammography without proof that the newest tests have 
affected the cancer-related mortality. Second, some tests 
discover lesions that are so early they may never become 
cancerous. For example, about 80% of young sexually 
active women may test positive for HPV1, which is the 
most of common cause of cervical cancer [13]. Only a 
small minority of these infections will eventually cause 
cancer, and this finding should not lead to a number of 
unnecessary hysterectomies.
Table 1: Intermediate end points of clinical trials and potential 
biases.
Intermediate end point Potential bias
Improved cancer-related 
survival in the screened 
population
Lead time bias: In reality the 
survival of the screened population 
has not been prolonged; only the 
duration of time during which they 
have been known to have cancer 
has been prolonged
Screening lead to 
diagnosis of cancer at an 
early stage
Length time bias: The cancers 
diagnosed through screening are 
less aggressive than those diag-
nosed when the patient is symp-
tomatic. In other words, some of 
the most aggressive cancers es-
cape screening, as they emerge 
in the interval during the screen-
ing sessions 
Screening leads to the 
diagnosis of more cancer
Over-Detection bias: most of 
the cancer diagnosed through 
screening may not become clin-
ically relevant during a person’s 
lifetime. This type of bias is of par-
ticular concern to older individuals 
with limited life expectancy.
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Possible benefits and risks of screening older indi-
viduals for cancer
Table 2 describes how age may affect cancer screening 
[10]. As the prevalence of cancer increases in the pop-
ulation, the specificity and the predictive value positive 
of screening tests improve as well, with reduction in the 
risk of false positive tests. Also, early detection of cancer 
may lead to increased use of minimally invasive surgery 
and lessen the need for emergency surgery, whose se-
rious complications, including death, increase with the 
patient’s age.
In the meantime the increased risk of competitive 
causes of death and of treatment complications may re-
duce the benefits of screening. For this reason, we advo-
cate in this article a policy of screening older individuals 
according to their physiologic age-that is, life expectancy 
and tolerance of stress-rather than chronologic age. Also, 
it is not clear how beneficial multiple serial screening 
sections may be, when most prevalence cases have been 
detected with the initial ones. 
Current Evidence of the Benefits of Screening 
Older Individuals with Cancer
Table 3 summarizes the evidence from randomized 
clinical trials that cancer screening is beneficial.
Breast cancer
A systematic review of 8 randomized controlled stud-
ies [14] indicates that a 15% approximate reduction in 
mortality risk may be obtained by screening asymp-
tomatic women for breast cancer ages 50-69 with serial 
mammograms. It is not clear how much the reduction in 
mortality was due to screening or to simultaneous im-
provement in cancer management including the use of 
adjuvant therapy. The same conclusions were reached by 
the U.S. Preventive Service Task Force [15], which issued 
a recommendation to screen average-risk women with 
biennial mammograms from ages 50-75. It is worthy of 
mention that mammography failed to effect a reduction 
in breast cancer-related mortality over 20 years of follow 
up in women ages 50-60 in the large Canadian study[16]. 
This study, which was highly publicized, compared phys-
ical examination of the breast by a professional and a sin-
gle-view screening mammography. This mammographic 
technique is now obsolete.
Circumstantial evidence suggests that screening 
mammography may be beneficial to older women. A ret-
rospective review of the Medicare-matched Surveillance 
Epidemiology and End Results (SEER) data demonstrat-
ed that serial mammograms reduced the risk of breast 
cancer-related mortality up to age 85 [17]. In a case-con-
trolled study, mammography up to age 80 was associated 
with a mortality reduction [18]. In a prospective study 
of breast cancer survivors with an age range of 65-85 
years, each mammogram was associated with a 0.69 fold 
decrease in the risk of breast cancer mortality [19]. In 
the meantime, in Vermont an inverse relation was found 
between the use of screening mammography and breast 
cancer deaths up to age 85 [20]. In a review of 7 studies 
exploring benefits and risks of mammography in wom-
en 65 and older, older women non affected by severe co 
morbidity appeared to experience an improved survival 
from serial mammography [21].
A number of questions remain unanswered including 
the role of new imaging techniques (breast MRI, 3D 
breast tomography), the ideal interval between screening 
sessions, and the value of clinical examination of the 
breast by a health-care professional.
Table 2: Advantages and disadvantages of cancer screening in the aged.
Advantages Disadvantages
•	 Increased prevalence of cancer  improved predictive value 
positive of screening tests
•	 Early diagnosis  reduced risk of complications from 
emergency surgery
•	 Increased cancer related mortality with age  possibility to 
improve overall survival 
•	 Reduced life expectancy  reduced survival benefits and 
risk of over-detection
•	 Decreased tolerance of stress  increased risk of diagnosis 
and treatment-related complications
•	 Decreased yield of cancer as a result of previous screening
Table 3: Benefits of cancer screening from randomized clinical trials.




Breast Mammography 50-69 Yes No
Large bowel Fecal Occult Blood (FOB)
Flexible sygmoidoscopy
50-80 Yes No
Lung Low-dose CT scan 55-75 Yes Yes
Prostate PSA 50-70 Yes No
Liver (hepatocellular) Circulating Alfa Fetoprotein (AFP) 
Liver US
40-70 Yes No
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Lung cancer
In a large randomized controlled study, yearly low 
dose CT of the lung reduced the risk of cancer-related 
(20%) and overall mortality (6%) in high risk individuals 
ages 55-75 [24]. Current smokers and ex-smokers who 
had quit the habit within 15 years were considered high 
risk. These results are particularly relevant to older indi-
viduals because lung cancer-related mortality increases 
with age [25] and mortality for lung cancer in the aged 
concerns mainly ex-smokers [26]. Lingering questions 
include the number of and the interval between screening 
sessions, the risk of exposure to low-dose radiation, and 
the benefits of screening beyond age 75 [27]. Until more 
data emerge, we feel that some form of screening should 
be offered to all individuals at risk with a life expectancy 
of 5 years or longer because lung cancer may be deadly in 
5 years, and safer alternatives to open thoracotomy exist 
today for the treatment of early disease. These include 
minimally invasive surgery [28], stereotactic radio sur-
gery [29], and radiofrequency and thermo-ablation [30].
Prostate cancer
The screening of asymptomatic men for prostate can-
cer with serial PSA determinations has been controver-
sial for the last 20 years, based on the impression that 
prostate cancer is generally an indolent disease and is 
not life-threatening, that the diagnostic confirmation of 
prostate cancer involved multiple prostate biopsies that 
were both painful and risky, and that the primary treat-
ment involved either radical prostatectomy or external 
beam radiation, both of which are associated with severe 
and permanent complications [31]. A recent random-
ized prospective study [32], showing that monitoring of 
localized prostate cancer was associated with the same 
10-year survival as immediate treatment with surgery or 
RT, reinforced this impression that screening for pros-
tate cancer is unnecessary and may be contra-indicat-
ed. In the same study the risk of metastatic disease at 10 
years was higher among men managed with monitoring. 
Thus, with longer follow-up, monitoring without im-
mediate treatment may lead to a poorer survival. Once 
again this finding indicates the need to base screening 
programs on life expectancy rather than chronologic age. 
For this reason we feel that the current USPSTF guide-
lines recommending against screening men 70 and older 
for prostate cancer should be reconsidered [33].
Three large randomized controlled trials [34-36] 
compared screening with serial PSA determinations and 
no screening. The PLCO (Prostate Lung Colon and Ova-
ry) study included men ages 55-74 undergoing yearly 
PSA determination for 6 years and yearly digital rectal 
examination by a health professional for 4 years. Screen-
ing did not improve disease-specific and overall survival 
Limited evidence indicates that some form of breast 
cancer screening may reduce mortality and morbidity of 
breast cancer in women with a life expectancy of at least 
5 years. As partial and even total mastectomy now can be 
performed with local anesthesia, the contraindications 
to breast surgery are becoming rarer and rarer, even for 
women of advanced age.
Colorectal cancer
Asymptomatic individuals may be screened for 
colorectal cancer with several methods [22] that include:
i. Serial fecal examinations for occult blood with guaiac 
(FOB) or Fecal Immunochemical Test (FIT)
ii. Serial fecal examination for DNA
iii. Serial endoscopies, which include sigmoidoscopies 
and colonoscopies
iv. Computed Tomographic Colonography (CTC). 
According to five randomized controlled studies, se-
rial sygmoidoscopy reduced the colorectal cancer mor-
tality by 27% by 10-11 years of follow up; and in five 
randomized controlled studies, serial determinations of 
FOB reduced it by 9-22% over a period of 9-30 years. De-
spite the absence of randomized controlled studies, se-
rial colonoscopies are commonly used, because they al-
low the detection and resection of adenomatous polyps, 
which are precancerous lesions, in addition to visualiz-
ing the whole large bowel [23]. The exact role of FIT and 
stool DNA in the detection of colorectal cancer is unde-
fined. Clearly both tests are more specific than FOB, and 
stool DNA is more sensitive but less specific than FIT.
Several studies explored the sensitivity of CTC in 
detecting colonic adenomas. Using colonoscopy as the 
gold standard, the sensitivity of CTC varied with the 
size of the tumor and ranged from 66% to 97%. CTC 
requires the same bowel preparation as colonoscopy and 
involves the risk of a small dose of radiation, but the risk 
of perforation is lower with CTC. It is unclear in which 
patients CTC may be more convenient and safer than 
colonoscopy.
The USPSTF recommends screening individuals ages 
50-75 for colorectal cancer [22]. Most randomized clini-
cal trials included individuals only up to age 80, however. 
We believe that life expectancy and tolerance of treat-
ment should determine the decision of screening older 
individuals, more so than chronologic age. Serial deter-
minations of FOB every 1-2 years, serial sigmoidoscopies 
every 3-5 years and serial colonoscopies every 10 years 
appear to be acceptable strategies. Most likely the colo-
noscopy is the most practical and convenient. As the risk 
of bowel perforation increases with age, CTC in lieu of 
colonoscopy may be indicated in some older individuals.
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be limited to a small number of individuals who are at in-
creased risk for prostate cancer.
The case of prostate cancer is paradigmatic of how 
one must approach cancer screening in the older person 
as a dynamic issue, whose variables include new and safer 
diagnostic and therapeutic interventions in addition to 
the aging of the population.
Hepatocellular carcinoma
The mortality of hepatocellular carcinoma may be 
reduced by screening individuals affected by hepatitis B 
and C with serial liver ultrasound and alpha fetoprotein 
determinations [44]. Any person at risk with a life expec-
tancy of 5 years or longer may benefit from this inter-
vention. This recommendation should also include indi-
viduals unable to tolerate a hepatectomy, as alternative 
forms of treatment [45,46], such as thermo-ablation or 
hepatic artery chemo and radio-embolization, or stereo-
tactic radio surgery, are tolerable even by frail patients.
Cervical cancer
There has been a progressive increase in the incidence 
and mortality of cervical cancer in older women [47]. 
The cause of this phenomenon is unknown and may be 
in part related to the prolongation of the sexual life of the 
aged. Current screening recommendations for cervical 
cancer are based on a large epidemiologic study showing 
that serial PAP smear examination of the cervix had led 
to a 75% decline in mortality of younger women [13,47]. 
The recommendation to stop screening at age 60 should 
be revisited in view of this spate of cervical cancers in 
later ages [47].
Screening Older Individuals for Cancer: A 
Dynamic Approach
As outlined in the previous review, four important fac-
tors influence the discussion of screening older individuals 
with cancer. These include the aging of the population, new 
insights in cancer biology, new insights in the assessment 
of aging that allows the practitioner to estimate individual 
physiologic age [48-54], and the development of safer and 
more specific diagnostic and treatment interventions. The 
combination of these elements represents a twofold chal-
lenge: how to collect new evidence and how to apply cur-
rent evidence to clinical decisions.
How to collect new evidence
Large randomized clinical trials may have become 
obsolete in the new reality. While we are still discussing 
the benefit of mammographic screening for breast can-
cer, new imaging techniques may make mammography 
outdated. In addition, due to strict selection criteria, ran-
domized controlled trials cannot encompass the diver-
[35]. However the majority of individuals in the control 
group had one or more assessment of serum PSA at some 
time in the course of the study based on the decision of 
their personal physicians, so the results of the study can 
hardly be taken as proof of screening ineffectiveness. The 
European trial [34] involved men ages 55-69, and screen-
ing consisted of determination of PSA every 4 years on 
average and reported a decline of prostate cancer-related 
mortality with screening but not of overall mortality. The 
investigators also demonstrated that 1,011 men would 
need to be screened and 37 cases of prostate cancer di-
agnosed to prevent one cancer death. Likewise the Gote-
borg trial [36] demonstrated that regular screening re-
duced the prostate cancer mortality rate by 50% in men 
ages 55-69, and 293 men would need to be screened and 
12 prostate cancers treated to prevent one death. Again, 
screening had no detectable effect on overall survival. 
Based on this data, the Cochrane review [37] concluded 
that a decline in prostate cancer-related mortality may 
be obtained through screening in men with a life expec-
tancy of 10-15 years and that the frequent and serious 
complications of biopsy and treatment may counteract 
the benefits of screening.
These conclusions should be mitigated by the 
following considerations of special interest in terms of 
aged men:
•	 The risk of prostate cancer-related deaths 
increases with age at diagnosis at least up to age 89 [38]. 
Given the aging of the population one may predict that 
the incidence and mortality of prostate cancer in older 
individuals will increase.
•	 Serial biopsies of prostate cancer in men under-
going active monitoring of prostate cancer demonstrated 
a progressive increase in the grade of the same prostate 
cancer [39] with the aging of the patient. Along the same 
lines, prostate cancers diagnosed after age 80 generally 
appear more aggressive than those diagnosed in younger 
men [40].
•	 Multi-parametric MRI is more specific than 
trans-rectal ultrasonography in identifying high-risk 
prostate lesions and may reduce the number of biopsies-
and related risk-necessary for diagnosing prostate cancer 
[41].
•	 New forms of treatment of localized disease-in-
cluding image-modulated radiation therapy, proton thera-
py, and cryosurgery-may be associated with minimal risk of 
complications [42].
•	 It may become possible to identify individuals at 
high risk of developing prostate cancer. In addition to fam-
ily history and ethnicity, these factors may include midlife 
PSA levels [43]. If these data are confirmed, screening may 
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mortality in women 75 (or 80) and older with a life 
expectancy of 5 years?
•	 Does the use of FIT or fecal DNA decrease the use- 
and the risks-of colonoscopy in persons 70 and older 
with a life expectancy of at least 5 years?
•	 Do biological markers of aging [48-51] predict mor-
tality risks better than clinical evaluation in patients 
undergoing screening?
The SEER data on mammography have demonstrated 
the usefulness of registry databases in providing information 
on long-term mortality risk and survival of older individuals 
following cancer screening. Thanks to electronic records, tu-
mor registries may be developed into rapid-learning databases 
[56]. These new instruments, exemplified by the ASCO cancer 
LinQ [56], may be ideal to collect and interpret information 
on the values of screening asymptomatic older individuals for 
cancer. Unlike traditional registries, rapid-learning databases 
may encompass the diversity of the older population and allow 
the estimate of the physiological age of each individual. In ad-
dition, they have the flexibility to accommodate new techno-
logical and biological information and the capability to analyze 
new information in a timely and efficient manner [55,56]. All 
sity of the older population in terms of life expectancy, 
tolerance of stress, functional independence and social 
support [55]. These elements determine one’s physiolog-
ic age and may determine the benefits and risks of sec-
ondary cancer prevention more than do chronologic age.
Still, long-term follow ups of past trials may provide 
important age-related information. For example, pros-
tate cancer screening trials may establish whether the 
screening of men in their late 60s results in a reduction of 
cancer-related mortality 20 years later, as early treatment 
of cancer may have prevented the development of a more 
aggressive cancer late in life. Likewise, age-related rec-
ommendations based on many of those trials may have 
become obsolete given the progressive increase inhuman 
life expectancy in addition to new biological insights and 
clinical developments.
As long as patients are selected on the basis of 
physiologic age [52-55], randomized controlled trials 
still have an important role in addressing age-specific 
specific questions such as:
•	 Do more sensitive breast-imaging techniques than 
mammograms reduce the risk of breast cancer related 
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Figure 1: Decision tree to guide the screening of older individuals for breast cancer.
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Aging is associated with chronic and progressive inflam-
mation, assessed with the inflammatory index; changes in 
DNA methylation, assessed with the epigenetic clock; and 
expression of anti proliferative genes, such as the expression 
of P16 INK4a in circulating lymphocytes. Each one of these 
biologic markers of aging predicts the risk of mortality and 
functional dependence in the general population of individ-
uals 65 and older [48-50]. For reasons not well understood, 
aging is also associated with decreased concentrations of 
Vitamin D in the circulation, and Vitamin D levels are also 
an independent variable, a harbinger of mortality in the old-
er population [51]. Seemingly, they may be utilized to fine-
tune the assessment of physiologic age. Assessment of the 
Redox status and telomere length have also been proposed 
as markers of aging [10]. However, the Redox status does 
not add additional information to the clinical assessment, 
and the inter individual variability of the telomere length is 
too high to provide a reliable marker of aging.
Conclusions
Cancer in the older aged person is an increasing-
ly common problem, and age is currently a risk factor 
for cancer-related mortality. This review demonstrates 
that secondary prevention (early diagnosis of cancer by 
screening asymptomatic individuals) may reduce can-
cer-related mortality in the older population.
The benefit of cancer screening may be lessened and 
the risk increased with age, due to an age-related decline 
in life expectancy and in tolerance of stress, which may 
include cancer treatment. Thus the decision to screen 
older individuals should be based on physiological rather 
than chronological age. Based on current information, it is 
reasonable to offer some form of screening to individuals 
with a life expectancy of 5 years or more for colorectal 
and lung cancer and to those with a life expectancy of 
10 years or more for breast and prostate cancer. It is also 
reasonable to extend screening for cervical cancer to 
women above age 60 if they still have a uterus.
Unanswered questions include:
•	 The role of new imaging techniques for early detection 
of breast cancer and of TIS and fecal DNA for early 
detection of colorectal cancer
patients included in the database should undergo the same ba-
sic clinical evaluation, including life expectancy and suitability 
for treatment (Figure 1).
Practical approach to screening older individuals 
for cancer based on current evidence
In Figure 1 we propose a decisional tree to establish 
which older individuals may benefit from cancer screen-
ing. The ability to tolerate treatment will be an issue only 
rarely. We have already illustrated how local treatment 
of lung, prostate and breast cancer may be minimally in-
vasive and well tolerated even by individuals with limited 
functional reserve.
The determination of physiologic age is critical to 
maximize the benefits and minimize the risk of screen-
ing (Table 4). Currently, the comprehensive geriatric as-
sessment (CGA) has been utilized for this purpose [56]. 
Based on the CGA, one may estimate the risk of can-
cer-unrelated mortality up to 9 years [52] and the risk of 
complications from some anti neoplastic treatment such 
as surgery and cytotoxic chemotherapy [53,57]. Of the 
tests of physical functions, the timed “get up and go” and 
the gait speed are probably the ones most widely used 
[58-59]. Both may predict the risk of death and the risk 
of functional dependence, but neither has been validat-
ed to predict the risk of complications from oncological 
treatments. There are at least two different constructs of 
frailty [60]: one includes a condition of increased risk of 
mortality, disability and institutionalization over a 10-
year period; the other involves a condition of almost ex-
hausted functional reserve for which minimal stress may 
precipitate functional dependence. The first concept has 
been operationalized in the now classic Fried’s criteria 
[60] and has never been studied in cancer patients. The 
second construct was operationalized in four different 
instruments of functional assessment in which frailty was 
the lowest functional status [61]. In a prospective study 
comparing the accuracy of the four instruments, frail-
ty was predictive of 1 year mortality in cancer patients 
70 and over. Frailty in this situation identifies patients 
with very limited life expectancy and tolerance of stress. 
Seemingly these individuals represent only a small fringe 
of those who are not candidates for cancer screening.
Table 4: Determination of physiologic age. 
Clinical determination Laboratory determination
Comprehensive Geriatric Assessment (CGA)
Tests of physical function
Frailty
Inflammatory status (inflammatory index)
Epigenetic clock (methylation status)
Concentration of P16 INK4a in circulating lymphocytes
Circulating levels of Vitamin D
Length of leukocyte telomere
Redox status
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